-
Mouse Anti-Human VEGFR-2/KDR
Mouse Anti-Human VEGFR-2/KDR
- 中文名称：
- Mouse Anti-Human VEGFR-2/KDR
- 英文名称：
- Mouse Anti-Human VEGFR-2/KDR
- 品牌：
- AAA Biotech
- 品牌介绍：
- AAA Biotech专注于为全球生命科学研究提供高品质的蛋白质研究工具，核心产品包括经严格验证的抗体、重组蛋白及ELISA试剂盒。
- 货号：
- AAA79115
- 规格：
- 0.1 mg|2x0.1 mg|3x0.1 mg|4x0.1 mg|5x0.1 mg
- 保存建议：
- Store at 2-8°C for up to 2 weeks
After initial reconstitution, prepare and store working aliquots at -20 to -80°C
Avoid freeze/thaw cycles
- 货期：
- 6-8周
- 来源宿主：
- Mouse
- 反应种属：
- Human
- 应用：
- WB (Western Blot), FCM/FACS (Flow Cytometry), IHC (Immunohistochemistry), ELISA
- 免责声明：
- *本产品仅供科研实验使用，不得用于临床诊断。*
- 其他：
克隆性:Monoclonal
同型:IgG
克隆号:[IgG1; EIC]
特异性:The antibody will detect native human VEGFR-2/KDR in ELISA experiments and on the surface of different human cell types.
纯度:Protein G Purified
形式：Sterile filtered antibody solution was lyophilized from PBS; does not contain stabilizers or preservatives
浓度：N/A
- 说明书：
Disruption of the precise balance of positive and negative molecular regulators of blood and lymphatic vessel growth can lead to myriad diseases. Although dozens of natural inhibitors of hemangiogenesis have been identified, an endogenous selective inhibitor of lymphatic vessel growth has not to our knowledge been previously described. A splice variant of the gene encoding vascular endothelial growth factor receptor-2 (VEGFR-2) that encodes a secreted form of the protein, designated endogenous soluble VEGFR-2 (esVEGFR- 2/KDR) has been described. The endogenous soluble esKDR inhibits developmental and reparative lymphangiogenesis by blocking VEGF-C function. Tissue-specific loss of esKDR in mice induced, at birth, spontaneous lymphatic invasion of the normally alymphatic cornea and hyperplasia of skin lymphatics without affecting blood vasculature. Administration of esKDR inhibited lymphangiogenesis but not hemangiogenesis induced by corneal suture injury or transplantation, enhanced corneal allograft survival and suppressed lymphangioma cellular proliferation. Naturally occurring esKDR thus acts as a molecular uncoupler of blood and lymphatic vessels; modulation of esKDR might have therapeutic effects in treating lymphatic vascular malformations, transplantation rejection and, potentially, tumor lymphangiogenesis and lymphedema.
